Mitral Valve Disease Market Size & Share, by End user (Hospitals, Cardiac Centers, Ambulatory Surgical Centers); Product; Material; Treatment; Type - Global Supply & Demand Analysis, Growth Forecasts, Statistical Report 2025-2034

Mitral Valve Disease Market - Regional Analysis

North America Market Insights

North America in the mitral valve disease market is considered to be the dominant region, with a projected market share of 42.3%, along with an 8.2% growth rate by the end of 2034. The market’s growth in the region is effectively fueled by an increase in the implementation of transcatheter therapies, along with the presence of innovative healthcare facilities. The U.S. is dominating the region, owing to Medicare coverage facilities for the majority of TMVR procedures, along with the provision of federal funding for healthcare. Besides, Canada is also contributing with funds allocated for cardiac care, along with a surge in outpatient TVMR and AI-based valve repairs.

The mitral valve disease market in the U.S. is effectively dominating the region, owing to rapid TVMR implementation, catering to 40.5% growth as of 2022, along with an upsurge in Medicaid and Medicare expenditure, accounting for USD 5.5 billion as of 2023. Besides, Medicaid generously covers more than 75% of TMVR procedures, of which USD 850 million has been provided in 2024. Meanwhile, AI-powered valve repairs, advancements in devices, and outpatient TMVR are other key trends that are uplifting the market in the overall country. For instance, NIH-funded clinical studies have demonstrated 28.5% rapid procedures, while CMS reimbursements for similar day discharges diminish expenses by 19.5%.

The mitral valve disease market in Canada is also significantly growing at a rate of 6.7%, which is highly driven by the provision of public healthcare investments, accounting for USD 3.4 billion as of 2023. Besides, Ontario is majorly leading the country’s exposure, with 20% increased spending on valve treatments over the past 4 years. Meanwhile, gaps in rural care, bioprosthetic valve preference, and provincial TMVR expansion are other key trends that are positively impacting the market in the country. For instance, the USD 55 million program of Alberta enhanced accessibility by almost 38%, while almost 72% of surgeries utilize tissue valves to combat anticoagulants.

North America Mitral Valve Disease Supply Chain & Trade Facilities (2022-2025)

Sources: FDA, NIH, CMS, AHRQ, Health Canada, CDC, Trade Commissioner

APAC Market Insights

Asia Pacific in the mitral valve disease market is the fastest-growing region, with an expected 22.1% by the end of the forecast timeline, owing to a rise in cardiovascular disease occurrence and an increase in the aging population. China is readily dominating the region with the largest revenue share, and is driven by administrative healthcare and medical expenditure since 2024. This is followed by India, with yearly growth through public funding to cater to untreated and undiagnosed patients. Malaysia and South Korea are following closely, and are rapidly incorporating affordable TMVR devices, with 22% and 32% increases in procedural volumes.

The mitral valve disease market in China is expected to hold 50% of the region’s share, which is fueled by the USD 4.4 billion administrative healthcare expenditure as of 2024. In addition, the country comprises 1.7 million patients diagnosed with MVD, with the TMVR integration increasing to 31.5% yearly, owing to acceptances for 5 regional devices as of 2023. Besides, the country’s National Reimbursement Drug List (NRDL) presently covers 3 cutting-edge bioprosthetic valves, diminishing out-of-pocket expenses by 34%. Therefore, all these factors are effectively responsible for bolstering the overall market in the country.

The mitral valve disease market in India is projected to account for 23% of the region’s market, with the provision of USD 2.1 billion in public funding as of 2023. In addition, the country caters to almost 2.5 million patients demanding treatment for the disease. Besides, localized players, such as TTK Healthcare, are effectively addressing poor accessibility with USD 2,500 mechanical valves by capturing 15.7% market share. Meanwhile, the Ayushman Bharat scheme generously covers valve surgeries for 520 million citizens, but only 8.5% are able to receive care, owing to shortages in hospitals. The aspect of low-cost bioprosthetics and private-public collaborations are other growth opportunity for the market growth in the country.

APAC Government Initiatives in Mitral Valve Disease (2022-2025)

Sources: Australian Government Health, MOH Malaysia, KFDA

Europe Market Insights

Europe in the mitral valve disease market is expected to hold a considerable share of 28.2% during the projected timeline. The market’s upliftment in the region is effectively propelled by the presence of progressive health and medical systems, along with a rise in the aging population. Germany is deliberately leading the region’s revenue, owing to yearly spending and reimbursement coverage solutions. This is followed by France, with increased provision of funds as a part of its health budget. The UK is also contributing to the NHS adoption of TMVR to combat waiting timelines. Besides all these factors, regional strategies, such as the €2.7 billion Health Data Space, have escalated AI-powered diagnostics, thereby suitable for market development.

The mitral valve disease market in Germany is dominating the overall region with 32.7% revenue share, which is driven by nearly 100% reimbursement coverage for TMVR, as well as the €4.1 billion in yearly healthcare expenditure. The country is also leading in outpatient TMVR integration, diminishing hospital accommodations by at least 50% and also saving €10,500 per procedure. Besides, more than 550 hybrid operating rooms, the country generously performs over 25,500 TMVR procedures every year, which is backed by AI-based diagnostics, further funded with €520 million, thus denoting a positive impact on the overall market.

The mitral valve disease market in France is projected to hold 22.7% of the region’s market by generously allocating 7.5% of its health budget, accounting for €1.3 billion for progressive treatment, such as bioprosthetic and TMVR valves. The French National Authority for Health has successfully fast-tracked 7 TMVR devices as of 2023, thereby bolstering the market incorporation by almost 19.5%. Besides, biosimilar anticoagulants have lowered expenses by 27.5%, while telecardiology programs have effectively aimed to cater to barriers in rural accessibility, thereby creating an optimistic outlook for the market in the country.